Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Nguyen LS, Bretagne M, Arrondeau J, et al. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J ImmunoTher Cancer 2022;10:e004699. doi: 10.1136/jitc-2022-004699.
This article has been corrected since it was first published online. In the ‘Case-report’ section, the dosage for intravenous abatacept in combination with oral ruxolitinib has been corrected to ‘15 mg two times daily’.